Abstract
Nanocrystals (NCs) are the class of solid dosage forms which utilizes the concept of nanoscience together with crystal nature of drug to achieve advantages in terms of solubility, dissolution, and physicochemical properties. Comparing with other solid dosage forms, NC often comes with so many challenges in terms of physical stability as well as chemical stability during the manufacturing process and storage. Therefore, physicochemical properties of nanocrystals, toxic effect on the human body, and application in drug delivery through the various routes of administration are critical step formulation of NCs. There are various techniques involved to ensure solid state uniformity in the NCs and its impact on therapeutic performance. This review article emphasizes on various solid-state characterization techniques that are used to evaluate NCs, their toxicity, and pharmaceutical application. Further, NC-based marketed formulation is also discussed in this review.
Similar content being viewed by others
References
Antiochia R, Bollella P, Favero G, Mazzei F. Nanotechnology-based surface plasmon resonance affinity biosensors for in vitro diagnostics. Int J Anal Chem. 2016;2016:1–15.
Aziz T, Fan H, Zhang X, Haq F, Ullah A, Ullah R, et al. Advance study of cellulose nanocrystals properties and applications. J Polym Environ. 2020;28:1117–28.
Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373–87.
Bott S, Hart W. Particle size analysis utilizing polarization intensity differential scattering. U.S. Patent 4 (953),978. 1990.
Castañeda L. A facile method for formulation of atenolol nanocrystal drug with enhanced bioavailability, nanocrystalline mat. IntechOpen; 2019. p. 1–14.
Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9:e1416.
Chai Z, Ran D, Lu L, Zhan C, Ruan H, Hu X, et al. Ligand-modified cell membrane enables the targeted delivery of drug nanocrystals to glioma. ACS Nano. 2019;13(5):5591–601.
Chen Z, Wu W, Lu Y. What is the future for nanocrystal-based drug-delivery systems? Ther Deliv. 2020;11(4):1–5.
Chogale MM, Ghodake VN, Patravale VB. Performance parameters and characterizations of nanocrystals: a brief review. Pharmaceutics. 2016;8(26):1–18.
Danley R. New heat flux DSC measurement technique. Thermochim Acta. 2002;395:201–8.
De Waard H, De Beer T, Hinrichs W, Vervaet C, Remon J, Frijlink H. Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: elucidation of the mechanism by in-line Raman spectroscopy. AAPS J. 2010;12:569–75.
Deng J, Huang L, Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm. 2010;390(2):242–9.
Dressman J, Amidon G, Reppas C. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15:11–22.
Drews T, Tsapatsis M. Model of the evolution of nanoparticles to crystals via an aggregative growth mechanism. Microporous Mesoporous Mater. 2007;101:97–107.
DuBohm B, Muller R. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. Pharm Sci Tech. 1999;2:336–9.
Duchene D, Ponchel G. Bioadhesion of solid oral dosage forms, why and how? Eur J Pharm Biopharm. 1997;44:15–23.
El-Batal AI, Elmenshawi SF, Ali AMA, Eldbaiky EG. Preparation and characterization of silymarin nanocrystals and phytosomes with investigation of their stability using gamma irradiation. Indian J of Pharm Edu and Res. 2018;52(4):1–10.
Ganta S, Paxton JW, Baguley BC, Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm. 2009;367(1–2):179–86.
Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res. 2008;10:845–62.
Gao L, Liu G, Ma J, Wang X, Zhou L, Li X, et al. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharm Res. 2013;30(2):307–24.
Gao Y, Wang J, Wang Y, Yin Q, Glennon B, Zhong J, et al. Crystallization methods for preparation of nanocrystals for drug delivery system. Curr Pharm Des. 2015;21:3131–9.
Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008;77:311–9.
Gigliobianco MR, Casadidio C, Censi R, Piera Di Martino PD. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics. 2018;10(3):1–29.
Gulsun T, Gursoy RN, Oner L. Nanocrystal technology for oral delivery of poorly water-soluble drugs. FABAD J Pharm Sci. 2009;34:55–65.
Hanafy A, Spahn H, Vergnault G, Grenier P, Grozdanis MT, Lenhardt T. Pharmacokinetic evaluation of oral fenofibrate nanosuspension and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev. 2007;59:419–26.
Hancock B, Carlson G, Ladipo D. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int J Pharm. 2002;241:73–85.
Hecq J, Deleers M, Fanara D, Vranckx H, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm. 2005;299:167–77.
Heimbach T, Fleisher D, Kaddoumi A. Overcoming poor aqueous solubility of drugs for oral delivery. Biotechnol: Pharm Asp. 2007;5:157–215.
Ige PP, Baria RK, Gattani SG. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Colloids Surf B: Biointerfaces. 2013;108:366–73.
Im SH, Jung HT, Ho MJ, Lee JE, Kim HT, Kim DY, et al. 2020. Montelukast nanocrystals for transdermal delivery with improved chemical stability. Pharmaceutics. 2020;12(1):1–18.
Jarvis M, Krishnan V, Mitragotri S. Nanocrystals: a perspective on translational research and clinical studies. Bioeng Transl Med. 2019;4(1):5–16.
Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111(1–2):56–64.
Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 2015;10:13–23.
Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340:126–33.
Keck C, Muller R. Characterisation of nanosuspensions by laser diffractometry. In: Proceedings of the Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS), Nashville, TN, USA; 2005.
Kipp J. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284:109–22.
Koneti V, Singh SK, Gulati M. A comparative study of top-down and bottom-up approaches for the preparation of nanosuspensions of glipizide. Powder Technol. 2014;256:436–49.
Kumar AN, Deecaraman M, Rani C. Nanosuspension technology and its applications in drug delivery. Asian J Pharm. 2009;3:168–73.
Kumar M, Shanthi N, Mahato AK, Soni S, Rajnikanth PS. Preparation of luliconazole nanocrystals loaded hydrogel for improvement of dissolution and antifungal activity. Heliyon. 2019;5:1–10.
Kumar M, Jha A, Madhu DR, Mishra B. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy. Expert Opin Drug Deliv. 2020:1–14. https://doi.org/10.1080/17425247.2020.1798401.
Lademann J, Richter H, Teichmann A. Nanoparticles—an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm. 2007;66:159–64.
Lang J, Roehrs R, Jani R. Ophtalmic preparations. In: Remington: the science and practice of pharmacy. Philadelphia: LippincottWilliams & Wilkins; 2006.
Lee J, Lee S, Choi J. Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm Sci. 2005;24:441–9.
Li YS, Church JS. Raman spectroscopy in the analysis of food and pharmaceutical nanomaterials. J Food Drug Anal. 2014;22:29–48.
Li Y, Dong L, Jia A, Chang X, Xue H. Preparation and characterization of solid lipid nanoparticles loaded traditional Chinese medicine. Int J Biol Macromol. 2006;38:296–9.
Li W, Yang Y, Tian Y, Xu X, Chen Y, Mu L, et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm. 2011;408(1–2):157–62.
Liandong H, Dongqian K, Qiaofeng H, Na G, Saixi P. Evaluation of high-performance curcumin nanocrystals for pulmonary drug delivery both in vitro and in vivo. Nanoscale Res Lett. 2015;10,381–90.
Liu T, Yu X, Yin H, Möschwitzer JP. Advanced modification of drug nanocrystals by using novel fabrication and downstream approaches for tailor-made drug delivery. Drug Del. 2019;26(1):1092–103.
Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125(1):91–7.
Lu Y, Li Y, Wu W. Injected nanocrystals for targeted drug delivery. Acta Pharm Sin B. 2016;6(2):106–13.
Mantzaris N. Liquid-phase synthesis of nanoparticles: particle size distribution dynamics and control. Chem Eng Sci. 2005;60:4749–70.
Manzanares D, Cen V. Endocytosis: the nanoparticle and submicron nanocompounds gateway into the cell. Pharmaceutics. 2020;12(371):1–22.
Merisko EL, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18:113–20.
Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63:427–40.
Mohammad IS, Hu H, Yin L, He W. Drug nanocrystals: fabrication methods and promising therapeutic applications. Int J Pharm. 2019;562:187–202.
Moribe K, Wanawongthai C, Shudo J, Higashi K, Yamamoto K. Morphology and surface states of colloidal probucol nanoparticles evaluated by atomic force microscopy. Chem Pharm Bull. 2008;56:878–80.
Moschwitzer J, Achleitner G, Pomper H, Müller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm. 2004;58(3):615–9.
Mosharraf M, Nystrom C. The effect of particle size and shape on the surface specific dissolution rate of micronized practically insoluble drugs. Int J Pharm. 1995;122:35–47.
Muheem A, Shakeel F, Warsi MH, Jain GK, Ahmad FJ. A combinatorial statistical design approach to optimize the nanostructured cubosomal carrier system for oral delivery of ubidecarenone for management of doxorubicin-induced cardiotoxicity: in vitro–in vivo investigations. J Pharm Sci. 2017;106(10):3050–65.
Muller R, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm. 2002a;237:151–61.
Muller RH, Jacobs C. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002b;19:189–94.
Muller RH, Gohla S, Keck CM. State of the art of nanocrystals-special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011;78(1):1–9.
Nanotechnology for drug delivery: global market for nanocrystals. Available at: https://www.researchandmarkets.com/research/ths3db/nanotechnology_for. Accessed May 17, 2020.
Oberdorster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol. 2005;2:8.
Oh N, Ji-Ho Park JH. Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomedicine. 2014;9(1):51–63.
Patzelt A, Richter H, Knorr F. Selective follicular targeting by modification of the particle sizes. J Control Release. 2011;150:45–8.
Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Control Release. 2014;183:51–66.
Peters K, Leitzke S, Diederichs JE, Borner K, Hahn H, Müller RH, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection. J Antimicrob Chemother. 2000;45(1):77–83.
Pignatello R, Bucolo C, Ferrara P, Maltese A, Pvleo A, Puglisi G. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci. 2002;6:53–61.
Rabinow B. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785–96.
Raghava Srivalli KM, Mishra B. Drug nanocrystals: a way toward scale-up. Saudi Pharm J. 2014;24(4):386–404.
Raja SN, Bekenstein Y, Koc MA, Fischer S, Zhang D, Lin L, et al. Encapsulation of perovskite nanocrystals into macroscale polymer matrices: enhanced stability and polarization. ACS Appl Mater Interfaces. 2016;8:35523–33.
Reid MS, Villalobos M, Cranston ED. Cellulose nanocrystal interactions probed by thin film swelling to predict dispersibility. Nanoscale. 2016;8:12247–57.
Salmaso S, Caliceti P. Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv. 2013;1:1–19.
Sawant KK, Patel MH, Patel K. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. Drug Dev Ind Pharm. 2016;42(5):758–68.
Schnitte M, Staiger A, Casper LA, Mecking S. Uniform shape monodisperse single chain nanocrystals by living aqueous catalytic polymerization. Nat Commun. 2019;10(2592):1–6.
Shafaie S, Hutter V, Cook MT, Brown MB, Chau DY. In vitro cell models for ophthalmic drug development applications. Biores Open Access. 2016;5(1):94–108.
Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399:129–39.
Song K, Zhu X, Zhu W, Xiaoyan Li X. Preparation and characterization of cellulose nanocrystal extracted from Calotropis procera biomass. Bioresour Bioprocess. 2019;6(45):1–8.
Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473–80.
Sun W, Tian W, Zhang Y, He J, Mao S, Fang L. Effect of novel stabilizers—cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals. Nanomed: Nanotechnol Biol Med. 2012;8(4):460–7.
Tangri P, Khurana S. Basics of ocular drug delivery systems. Int J Res Pharmaceut Biomed Sci. 2011;2(4):1541–52.
Thakur RR, Kashiv M. Modern delivery systems for ocular drug formulations: a comparative overview WRT conventional dosage form. Int J Res Pharmaceut Biomed Sci. 2011;2:8–18.
Van Eerdenbrugh B, Vermant J, Martens JA, Froyen L, Van Humbeeck J, Augustijns P, et al. A screening study of surface stabilization during the production of drug nanocrystals. J.Pharm.Sci. 2009;98(6):2091–103.
Xia D, Quan P, Piao H, Piao H, Sun S, Yin Y, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40(4):325–34.
Young TJ, Mawson S, Johnston KP, Henriksen IB, Pace GW, Mishra AK. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotechnol Prog. 2000;16(3):402–7.
Zucca N, Erriu G, Onnis S, Longoni A. An analytical expression of the output of a power compensated DSC in a wide temperature range. Thermochim Acta. 2002;143:117–25.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jahangir, M.A., Imam, S.S., Muheem, A. et al. Nanocrystals: Characterization Overview, Applications in Drug Delivery, and Their Toxicity Concerns. J Pharm Innov 17, 237–248 (2022). https://doi.org/10.1007/s12247-020-09499-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12247-020-09499-1